SuperworthTravere Therapeutics TVTX
- Market cap
- $4.7B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 8.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $591.3M
- +77% on a year ago
- Net margin
- −7.4%
- Free cash flow yield
- n/m
- not a meaningful number
Travere Therapeutics trades at 8.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $591.3M over the last twelve months, up 77% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $37.1M+32% | $45.1M+54% | $41.4M+34% | $54.1M+68% | $62.9M+70% | $74.8M+66% | $81.7M+98% | $114.4M+112% | $164.9M+162% | $129.7M+73% | $127.2M+56% | $169.6M+48% | |
| Cost of revenue | $1.3M+16% | $4.6M+426% | $1.5M−64% | $2.1M+42% | $1.6M+26% | $2.6M−44% | $4.7M+211% | $1.5M−26% | $1.6M−3% | $2.6M+0% | $1.9M−58% | $2.2M+43% |
| Gross profit | $35.8M+33% | $40.5M−25% | $39.9M+49% | $52.1M+69% | $61.3M+71% | $72.2M+78% | $77.1M+93% | $112.9M+117% | $163.3M+167% | $127.1M+76% | $125.2M+63% | $167.4M+48% |
| R&D | $60.6M+6% | $59.7M−1% | $49.4M−15% | $54.3M−18% | $51.7M−15% | $62.1M+4% | $46.9M−5% | $49.4M−9% | $51.9M+0% | $57.9M−7% | $57.1M+22% | $60.3M+22% |
| SG&A | $67.8M+29% | $63.6M+1% | $64.2M−3% | $64.8M−5% | $65.6M−3% | $69.5M+9% | $60.4M−6% | $62.6M−3% | $86.5M+32% | $101.7M+46% | $80.3M+33% | $96.1M+54% |
| −$92.6M+12% | −$94.2M+9% | −$139.2M+43% | −$67.7M−35% | −$56.1M−39% | −$60.7M−36% | −$42.7M−69% | −$12.7M−81% | $24.9M | −$32.4M−47% | −$36.9M−14% | $4M | |
| Interest expense | $2.8M+1% | $2.8M+1% | $2.8M−3% | $2.8M−2% | $2.8M−2% | $2.8M−0% | $2.9M+2% | $2.8M+2% | $2.8M−1% | $2.3M−19% | $2.3M−20% | $2.1M−25% |
| Pre-tax income | −$89.2M+6% | −$88.5M+4% | −$135.8M+41% | −$69.6M−32% | −$54.8M−39% | −$60.3M−32% | −$41.2M−70% | −$12.7M−82% | $25.7M | −$21.1M−65% | −$36.7M−11% | −$35M+175% |
| $12K−92% | $68K+8% | $191K+145% | $85K+31% | −$84K | −$72K | $39K−80% | $20K−77% | $8K | $921K | −$120K | −$204K | |
| Net income | $150.7M | −$90.2M+37% | −$136.1M+58% | −$70.4M−18% | −$54.8M | −$60.3M−33% | −$41.2M−70% | −$12.8M−82% | $25.7M | $2.7M | −$37.1M−10% | −$34.8M+173% |
| $1.97 | −$1.18+15% | −$1.76+39% | −$0.91−20% | −$0.70 | −$0.73−38% | −$0.47−73% | −$0.14−85% | $0.28 | $0.03 | −$0.40−15% | −$0.37+164% | |
| 76.3M+19% | 76.5M+19% | 77.1M+13% | 77.5M+2% | 77.8M+2% | 83.1M+9% | 88.4M+15% | 88.9M+15% | 102.6M+32% | 90.3M+9% | 91.9M+4% | 93.5M+5% |
Revenue: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Gross profit: 50 periods, Q1 FY14 to Q2 FY26: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
Net income: Q1 FY10 and Q1 FY11: 6 months less the 3 months printed beside them.
EPS, diluted: 14 periods, Q1 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 12 periods, Q4 FY12 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TVTXTravere Therapeutics | $4.7B | n/m | 16.0× | 8.0× | +77% | −7.4% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| Peer median | $5B | 31.5× | 28.9× | 5.8× | +34% | 18.1% |
Investors who own it
Investors we follow who held Travere Therapeutics at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital0.0% of portfolionew
More on Travere Therapeutics
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .